Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs Ishares Msci Thailand Etf (THD) Price & Performance

Mesoblast LimitedTrade
Ishares Msci Thailand EtfTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs Ishares Msci Thailand Etf — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Ishares Msci Thailand Etf trades at $73.53. The key difference: Ishares Msci Thailand Etf is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

MESOTHD
Market Cap
$2.17B
Sector
TechnologyBroad Market / Factor
52-Week High
$20.96$75.05
52-Week Low
$12.88$55.83
Enterprise Value
$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.

Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.

Ishares Msci Thailand Etf

THD trades at $73.02, up 0.21% on the day, with a bullish technical outlook supported by moving averages and an upcoming dividend of $1.71 scheduled for June 2026. Recent news highlights its strong performance, with nearly 38% total returns over the past year, driven by exposure to AI hardware plays like Delta Electronics. The stock's momentum is reinforced by positive sentiment from financial media, though key financial ratios remain undisclosed in the provided data.

Outlook is cautiously optimistic due to technical strength and AI-driven growth potential, but risks include vulnerability to profit-taking and macroeconomic factors. Investors should monitor earnings reports for fundamental validation, as current data lacks detailed financial metrics. The stock faces competition and regional economic shifts, requiring careful assessment of future guidance.

Returns comparison

Trailing returns across standard periods

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO

About Ishares Msci Thailand Etf

THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.

Read more on THD